Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
Key Financial Performance
Revenue for Q2 2025 $1.7 million, a year-over-year decline of 21%. The decline was primarily due to an industry-wide issue with the sterilization vendor, resulting in a temporary back order of approximately $400,000 in revenue.
Pediatric Revenue Increased by 23% compared to Q2 2024. This growth reflects strong demand from established hospital customers and interest from new centers.
Heart Failure Revenue Declined by 53% compared to Q2 2024. The decline was significantly impacted by the temporary back order.
Critical Care Revenue Declined by 35% compared to Q2 2024. The decline was significantly impacted by the temporary back order.
Gross Margin 55.5% compared to 67.2% in Q2 2024. The decrease was largely due to under-absorption of fixed overhead because of lower production volumes.
Selling, General and Administrative Expenses $3.2 million, flat compared to Q2 2024.
Research and Development Expense $675,000, a slight increase compared to $558,000 in Q2 2024.
Total Operating Expenses $3.9 million, a 2% increase over Q2 2024.
Operating Loss $2.9 million, compared to $2.3 million in Q2 2024. The increase reflects higher operating expenses.
Net Loss Attributable to Common Shareholders $12.6 million, or a loss of $60.99 per share, compared to $7.7 million, or a loss of $791.82 per share in Q2 2024. The increase in net loss is due to higher operating losses and other financial factors.
Cash and Cash Equivalents $4.5 million at the end of Q2 2025, with no debt. The recent $5 million gross capital raise bolstered the financial position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Aquadex: Continued strong demand in pediatrics and increasing adoption in critical care. Focused on outpatient heart failure opportunities, refining support tools, and enhancing site engagement programs.
Pediatrics: Revenue increased by 23% compared to Q2 2024, driven by strong demand and interest from new centers.
Critical Care: Increasing adoption as accounts move from trialing to consistent practice, particularly in post-cardiac surgery fluid management.
Outpatient Heart Failure: Efforts centered on outpatient clinics, showing value as a cost-efficient alternative.
Manufacturing Transition: Transitioning to KDI Precision Manufacturing by October, expected to result in operational efficiencies and cost savings over the next 12 months.
REVERSE-HF Clinical Trial Termination: Terminated the trial to reallocate $4 million to higher-impact growth areas, not due to device performance or safety concerns.
Growth Strategy: Focused on cardiac surgery, pediatrics, and outpatient heart failure. Expanding reimbursement and clinical need for broader access to ultrafiltration.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue decline: Revenue for the second quarter was $1.7 million, a year-over-year decline of 21%, primarily driven by a temporary product back order due to an industry-wide issue with the sterilization vendor.
Product back order: The temporary back order caused approximately $400,000 in lost revenue and significantly impacted heart failure and critical care revenue, which declined by 53% and 35%, respectively.
Gross margin decline: Gross margin for the quarter dropped to 55.5% from 67.2% in Q2 2024, largely due to under-absorption of fixed overhead because of lower production volumes.
Operating loss: Operating loss for Q2 was $2.9 million, compared to $2.3 million in Q2 2024, reflecting increased operational challenges.
Net loss: Net loss attributable to common shareholders was $12.6 million, significantly higher than the $7.7 million loss in Q2 2024, indicating worsening financial performance.
Manufacturing transition risks: The planned transition to KDI Precision Manufacturing by October could pose risks related to operational disruptions or delays, despite expected cost savings.
Termination of REVERSE-HF trial: The termination of the REVERSE-HF clinical trial reallocates $4 million but may limit future evidence-building for inpatient heart failure, potentially impacting strategic opportunities.
Challenges in outpatient heart failure scaling: Scaling outpatient heart failure programs faces challenges such as staffing, space, and operational complexities, which could hinder broader adoption of Aquadex.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Transition to KDI Precision Manufacturing: The company plans to transition its manufacturing to KDI Precision Manufacturing by October, expecting meaningful operational efficiencies and cost savings over the next 12 months.
Termination of REVERSE-HF Clinical Trial: The company terminated the REVERSE-HF clinical trial to reallocate approximately $4 million toward higher impact growth areas, focusing on cardiac surgery, pediatrics, and outpatient heart failure.
Cardiac Surgery Growth Strategy: The company aims to expand the use of Aquadex in managing postoperative fluid overload and protecting renal function in cardiac surgery patients.
Pediatrics Growth Strategy: Aquadex remains a viable fluid management option for children with little to no kidney function, and the company plans to continue focusing on this segment.
Outpatient Heart Failure Growth Strategy: The company sees expanded reimbursement and clinical need paving the way for broader access to ultrafiltration in outpatient heart failure programs.
Financial Priorities: The company is focused on progressing towards being cash flow positive and delivering on commercial targets in pediatrics and cardiac surgery.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:You mentioned the issue with the vendor regarding sterilization and believe that accounts for around $400,000 in revenue. It sounds like that was resolved. If so, when was it resolved? And will there be any impact in the current third quarter that we're in?
A:The issue was resolved in the first week of July. The company is no longer in back order and is building finished good inventory rapidly in preparation for the transfer to KDI Manufacturing. The sterilization provider is fully operational with all chambers available. The impact was primarily in heart failure and cardiac surgery as inventory was allocated to pediatrics, which saw growth due to demand and product availability.
Q:Where do you see right now the largest opportunity? Is it pediatrics? Is it critical care, heart failure? Is it all 3? And which one though specifically do you see the most opportunity?
A:The largest opportunities are in pediatrics, critical care (especially cardiac surgery), and heart failure. Pediatrics is growing as more children's hospitals adopt Aquadex for treating small babies with kidney issues. Cardiac surgery is growing as physicians use Aquadex to remove fluid more efficiently after open-heart surgery, reducing ICU time. Heart failure is expected to grow the fastest due to increased outpatient reimbursement from $413 to $1,639 per day. Several hospitals are setting up outpatient clinics, and the first patient has already been treated at Prisma Richland hospital.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity in the responses provided by management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act assumption
Aquadex FDA
Aquadex ability
Aquadex value
CEO President
Care order
Chairman Chief
Chairman Leah
Commission obligation
Communications today
Conference Instructions
Corporate Participant
Director Communications
ET day
Erb Leah
FDA device
Failure Critical
Group LLC
HF area
Instructions pleasure
Instructions today
Investor page
LLC Conference
Leah McMullen
Leah fundamental
Manufacturing live
McMullen Corporate
McMullen Director
Nuwellis opportunity
REVERSE HF
access
cost
decision
function
hospital
interest
investment
kidney
outpatient heart
study
surgery
NUWE Transcript
Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call indicates a positive sentiment due to a 15% revenue increase and improved gross margin from 60% to 65%. Despite a net loss, the reduction from $1.5 million to $1.2 million signals progress. The company's focus on high-growth segments and strategic initiatives further supports a positive outlook. However, the absence of guidance and increased operating expenses slightly temper enthusiasm. Overall, the financial performance and strategic focus suggest a positive stock price movement in the short term.
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call presents a mixed picture. While there are some positive aspects such as increased gross margins and strategic focus areas, there are significant concerns. The company faces liquidity constraints, operating losses, and supply chain risks. The international market challenges and increased operating expenses add to the negative sentiment. Despite the optimistic guidance for 2026, the current financial health and operational challenges are likely to weigh on the stock price, leading to a negative sentiment prediction.
Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-12
The earnings call reveals several challenges: a 6% revenue decline, reduced gross margins, increased operating expenses, and a higher operating loss. Despite some positive aspects like sequential revenue growth and a focus on U.S. market expansion, the termination of international operations and dependency on the U.S. market pose risks. The cash position is limited, and manufacturing transition risks exist. With no new partnerships or positive shareholder return plans discussed, the overall sentiment is negative, likely leading to a -2% to -8% stock price movement.
Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
NUWE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
